PL369449A1 - Solwaty chlorowodorku lerkanidypiny i nowe krystaliczne postacie chlorowodorku lerkanidypiny - Google Patents

Solwaty chlorowodorku lerkanidypiny i nowe krystaliczne postacie chlorowodorku lerkanidypiny

Info

Publication number
PL369449A1
PL369449A1 PL02369449A PL36944902A PL369449A1 PL 369449 A1 PL369449 A1 PL 369449A1 PL 02369449 A PL02369449 A PL 02369449A PL 36944902 A PL36944902 A PL 36944902A PL 369449 A1 PL369449 A1 PL 369449A1
Authority
PL
Poland
Prior art keywords
lercanidipine hydrochloride
solvates
crystalline forms
new crystalline
lercanidipine
Prior art date
Application number
PL02369449A
Other languages
English (en)
Inventor
Amedeo Leonardi
Iasi Gianluca De
Fausto Bonifacio
Original Assignee
Recordati Ireland Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Recordati Ireland Limited filed Critical Recordati Ireland Limited
Publication of PL369449A1 publication Critical patent/PL369449A1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL02369449A 2001-08-06 2002-08-05 Solwaty chlorowodorku lerkanidypiny i nowe krystaliczne postacie chlorowodorku lerkanidypiny PL369449A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT2001MI001727A ITMI20011727A1 (it) 2001-08-06 2001-08-06 Solvati della lercanidipina cloridrato e nuove forme cristalline della lercanidipina cloridrato ottenute da essi

Publications (1)

Publication Number Publication Date
PL369449A1 true PL369449A1 (pl) 2005-04-18

Family

ID=11448246

Family Applications (1)

Application Number Title Priority Date Filing Date
PL02369449A PL369449A1 (pl) 2001-08-06 2002-08-05 Solwaty chlorowodorku lerkanidypiny i nowe krystaliczne postacie chlorowodorku lerkanidypiny

Country Status (21)

Country Link
EP (1) EP1423367B1 (pl)
JP (1) JP2005502648A (pl)
KR (1) KR100912664B1 (pl)
CN (1) CN100494175C (pl)
AR (1) AR037230A1 (pl)
AT (1) ATE294162T1 (pl)
AU (1) AU2002331390B2 (pl)
BR (1) BR0211738A (pl)
DE (1) DE60203919D1 (pl)
EA (1) EA200400279A1 (pl)
ES (1) ES2209684T1 (pl)
HR (1) HRP20040157A2 (pl)
HU (1) HUP0401161A3 (pl)
IL (2) IL153916A0 (pl)
IT (1) ITMI20011727A1 (pl)
MX (1) MXPA04001073A (pl)
NO (1) NO20040479L (pl)
PE (1) PE20030350A1 (pl)
PL (1) PL369449A1 (pl)
UY (1) UY27409A1 (pl)
WO (1) WO2003014085A1 (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100651212B1 (ko) 2004-10-27 2006-12-01 제일약품주식회사 무정형 레르카니디핀의 제조방법
AR052918A1 (es) 2005-02-25 2007-04-11 Recordati Ireland Ltd Clorhidrato de lercanidipina amorfo
US8097729B2 (en) 2005-09-16 2012-01-17 Glenmark Generics Ltd. Polymorphic form of lercanidipine hydrochloride and process for the preparation thereof
WO2008107797A2 (en) * 2007-03-05 2008-09-12 Actavis Group Ptc Ehf Lercanidipine hydrochloride polymorphs and an improved process for preparation of 1,1,n-trimethyl-n-(3,3-diphenylpropyl)-2-aminoethyl acetoacetate
WO2008136392A1 (ja) * 2007-04-27 2008-11-13 Ajinomoto Co., Inc. 経口投与用製剤
WO2011161223A2 (en) 2010-06-23 2011-12-29 Krka, Tovarna Zdravil, D.D., Novo Mesto Pharmaceutical oral dosage forms comprising lercanidipine and enalapril and their pharmaceutically acceptable salts
SI2654729T1 (sl) 2010-12-24 2016-08-31 Krka, D.D., Novo Mesto Homogene farmacevtske oralne dozirne oblike, ki obsegajo lerkanidipin in enalapril ali njune farmacevtsko sprejemljive soli skupaj z organsko kislino

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8403866D0 (en) 1984-02-14 1984-03-21 Recordati Chem Pharm Diphenylalkylaminoalkyl esters
US5767136A (en) * 1995-05-12 1998-06-16 Recordati, S.A. Chemical And Pharmaceutical Company 1,4-Dihydropyridines useful for prevention or reduction of atherosclerotic lesions on arterial walls

Also Published As

Publication number Publication date
KR100912664B1 (ko) 2009-08-17
DE60203919D1 (de) 2005-06-02
AR037230A1 (es) 2004-11-03
NO20040479L (no) 2004-02-03
EP1423367B1 (en) 2005-04-27
ATE294162T1 (de) 2005-05-15
WO2003014085A1 (en) 2003-02-20
ITMI20011727A0 (it) 2001-08-06
MXPA04001073A (es) 2005-02-17
AU2002331390B2 (en) 2008-06-05
IL153916A0 (en) 2003-07-31
JP2005502648A (ja) 2005-01-27
HUP0401161A2 (hu) 2004-09-28
ITMI20011727A1 (it) 2003-02-06
BR0211738A (pt) 2004-09-28
EA200400279A1 (ru) 2004-06-24
ES2209684T1 (es) 2004-07-01
HUP0401161A3 (en) 2009-04-28
CN1538958A (zh) 2004-10-20
PE20030350A1 (es) 2003-06-06
CN100494175C (zh) 2009-06-03
KR20040030932A (ko) 2004-04-09
EP1423367A1 (en) 2004-06-02
IL153916A (en) 2008-07-08
HRP20040157A2 (en) 2004-08-31
UY27409A1 (es) 2003-03-31

Similar Documents

Publication Publication Date Title
EP2492264A3 (en) Biaryl Heterocyclic Compounds And Methods Of Making And Using The Same
NO20042739L (no) Farmasoytiske sammensetninger av 5,6,14-triazatetracyklo(10.3.1.0(2,11).0(4,9))-heksadeca-2(11)3,5,7,9-pentan
EA200401169A1 (ru) Аминометилзамещенные тетрациклиновые соединения
WO2004074244A3 (en) Pyrimidine compounds
WO2004004657A3 (en) Hiv integrase inhibitors
WO2005011592A3 (en) Substituted indazole-o-glucosides
WO2005012243A3 (en) Substituted indole-o-glucosides
MY145074A (en) Thiazolidin-4-one derivatives
NO20033732L (no) N-substituerte ikke-aryl-heterosykliske NMDA/NR2B-antagonister, og farmasoytiske preparater som omfatter slike forbindelser.
WO2003024955A3 (en) Small molecule inhibitors of caspases
WO2003029264A3 (en) 2-propynyl adenosine analogs having a2a agonist activity and compositions thereof
WO2001098236A3 (en) 7-phenyl-substituted tetracycline compounds
WO2003095455A3 (en) Substituted pyrazolopyrimidines
NO20054787D0 (no) Indenderivater som farmasotiske midler
HK1062885A1 (en) Spiropyrazole compounds
NO20082330L (no) Nye krystallinske polymorfe former av lerkanidipinhydroklorid og fremgangsmate for fremstilling derav
CL2004001085A1 (es) Compuestos derivados de quinolil propil piperidina, procedimiento de preparacion; compuesto intermediario; composicion farmaceutica, utiles como agentes microbianos.
AP2002002616A0 (en) Antidibetic agents
WO2003053971A8 (en) Pyridoquinoxaline antivirals
WO2005035537A3 (en) Substituted tricyclic heterocycles and their uses
TWI256304B (en) Pharmaceutical compositions based on azetidine derivatives
PL369449A1 (pl) Solwaty chlorowodorku lerkanidypiny i nowe krystaliczne postacie chlorowodorku lerkanidypiny
WO2001004116A3 (en) Neurotrophic pyrrolidines and piperidines, and related compositions containing them
WO2005065047A3 (en) Stable oral composition containing desloratadine
WO2004087652A3 (en) Imidazotriazine compounds